FDA approve 600mg darunavir tablet

On 26 February, the FDA approved a 600mg tablet formulation of the protease inhibitor darunavir (Prezista).

Tibotoc, manufacturers of this drug, say that they expect the new formulation to be widely available in the US from May 2008, requiring fewer daily pills than the current 300mg formulation.

Source: FDA list serve/Tibotec PR

Links to other websites are current at date of posting but not maintained.